tirzepatide cardiovascular outcome trial In patients with type 2 diabetes and atherosclerotic disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT results: https://nej.md/4qd5rLx SURPASS-CVOT Published: Large Trial Confirms
Description
10.1016/j.sjbs.2021.12.060 41 MatsosA.LoomesM.ZhouI.MacmillanE.SabelI.RotziokosE.et al (2017)
May your protein stay high, your hydration stay consistent, and your meals stay nourishing.
Changes in estimated glomerular filtration rate, systolic or diastolic blood pressure, cholesterol (LDL, total cholesterol), weight, hemoglobin A1c, urine albumincreatinine ratio, and body mass index were compared at baseline to last value in the specified period
K., Liu, B., Cui, X., & Brown, K
Ongoing monitoring to ensure Tirzepatide dose adjustments are made for optimal results
